Novelix Pharmaceuticals files Reg 29(2) notice on share acquisition by Srinidhi Fine-Chemicals LLP and Narahari Belide

What Novelix Pharmaceuticals announced

On 11 July 2026, Novelix Pharmaceuticals Ltd (BSE: 536565) filed a disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The filing informs the market that Srinidhi Fine‑Chemicals LLP and Narahari Belide have acquired shares in Novelix that meet the criteria for a substantial acquisition.

The filing itself contains no quantitative details such as the number of shares bought, the percentage of total equity acquired, or the consideration paid. It merely records the identity of the acquirers and confirms that the statutory reporting requirement has been satisfied.

Parties involved

• Srinidhi Fine‑Chemicals LLP – a limited liability partnership engaged in the chemicals business.
• Narahari Belide – an individual investor whose background is not disclosed in the filing.

Both parties are now subject to the ongoing disclosure obligations that accompany a substantial shareholding under SEBI rules, including any further increase in stake or any change in control.

Regulatory context

Regulation 29(2) of the SEBI (SAST) Regulations, 2011 mandates that any person or entity acquiring shares that cross a prescribed threshold (generally 5 % of the paid‑up capital) must promptly disclose the acquisition to the stock exchange. The purpose is to ensure transparency for investors and to monitor potential changes in control.

The filing by Novelix satisfies this requirement, signalling that the company is compliant with the regulatory framework. No additional approvals, such as from the board or shareholders, are required merely by virtue of the filing.

Key facts at a glance

Why this matters for investors

The disclosure confirms that two new shareholders have crossed the regulatory threshold, which may affect the composition of Novelix’s shareholding pattern. While the filing does not reveal the size of the stake, any substantial holder gains certain rights, such as the ability to call for a shareholders’ meeting if the stake exceeds 10 %.

Investors should monitor subsequent filings for updates on the exact shareholding percentage, any further acquisitions, or any intent to influence corporate strategy. The presence of a chemicals‑focused LLP could also hint at strategic synergies, but the filing itself does not provide such context.

Conclusion

Novelix Pharmaceuticals has complied with SEBI’s disclosure requirements by reporting that Srinidhi Fine‑Chemicals LLP and Narahari Belide have acquired shares that trigger a Reg 29(2) filing. The notice does not disclose the size of the holdings, and no immediate corporate actions are indicated. Market participants should watch for future disclosures that may reveal the exact stake and any related strategic intentions.